Investor Presentaiton
Non-GAAP measures - adjusted EPS (cont.)
Three Months Ended Oct 31, 2022
Three Months Ended Oct 31, 2021
Percent
Change
Diluted earnings per share:
Reported EPS
$(0.66)
$1.11
NM
Adjustments:
Pre-Tax
Impact
Tax
Unrealized and realized (gains) and losses on equity and other investments
Opioid legal charges
$1.34
Impact
$(0.24)
NCI
Impact³
$0.01
Pre-Tax
Tax
NCI
Net Impact
Impact
$1.11
$(0.42)
Impact'
$0.09
Impact³
Net Impact
$(0.33)
1.22
(0.17)
1.05
Loss on extinguishment of debt
0.86
(0.19)
Net Adjustments*
$2.16
0.67
$0.34
Adjusted EPS4
$1.50
$1.45
+3.4%
Three Months Ended Jul 31, 2022
Three Months Ended Jul 31, 2021
Percent
Change
Diluted earnings per share:
Reported EPS
$1.88
$1.52
+23.7%
Adjustments:
Unrealized and realized (gains) and losses on equity and other investments
Gain on sale of equity method investment in Brazil
Pre-Tax
Impact
$0.14
Tax
NCI
1,2
Impact"
$(0.02)
Impact³
$(0.01)
Net Impact
$0.11
Pre-Tax
Impact
$0.34
Tax
Impact
$(0.08)
NCI
Impact³
Net Impact
$0.26
(0.16)
(0.16)
Discrete tax item
(0.06)
(0.06)
Net Adjustments
$(0.11)
$0.26
Adjusted EPS
$1.77
$1.78
-0.6%
2
1 Tax impact calculated based on nature of item, including any realizable deductions, and statutory rate in effect for relevant jurisdictions.
No tax expense was incurred in connection with the gain on sale of equity method investment in Brazil.
3 Calculated based on the ownership percentages of our noncontrolling interests, where applicable.
4
Adjusted EPS for the three months ended October 31, 2022 was calculated using weighted average shares outstanding of 2,720 million, which includes the dilutive impact of share-based payment awards.
NM not meaningfulView entire presentation